<DOC>
	<DOCNO>NCT00005087</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Colony-stimulating factor filgrastim may increase number immune cell find bone marrow peripheral blood may help person 's immune system recover side effect chemotherapy . Radiation therapy use high-energy x-rays damage tumor cell . PURPOSE : Phase II trial study effectiveness paclitaxel , cisplatin , filgrastim combine radiation therapy treat patient locally recurrent head neck cancer receive previous treatment radiation therapy .</brief_summary>
	<brief_title>Paclitaxel , Cisplatin , Filgrastim Combined With Radiation Therapy Treating Patients With Locally Recurrent Head Neck Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine median , one-year , long-term ( defined two-year ) disease-free survival overall survival patient previously irradiate locally recurrent squamous cell cancer head neck treat paclitaxel , cisplatin , filgrastim ( G-CSF ) combine radiotherapy . - Determine rate acute late toxic effect regimen patient . - Determine pattern disease progression patient treat regimen . OUTLINE : Patients undergo radiotherapy twice daily ( 4-6 hour apart ) day 1-5 . Patients receive paclitaxel IV 1 hour begin immediately completion first fraction radiotherapy complete less 3 hour start second fraction radiotherapy day 1-5 . Patients receive cisplatin IV 30 minute begin immediately completion paclitaxel infusion day 1-5 filgrastim ( G-CSF ) subcutaneously day 6-13 . Treatment repeat every 2 week 4 course absence disease progression unacceptable toxicity . Patients initially respond therapy develop recurrence resectable lesion ( inside outside retreatment field ) may undergo surgical resection . Patients follow 4 week completion radiotherapy , every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 100 patient accrue study within 34 month .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove locally recurrent primary squamous cell cancer ( SCC ) head neck second primary SCC head neck More 1 prior recurrence allow first recurrence occur least 6 month completion prior radiotherapy Disease must confine head neck ( clavicle ) No primary SCC nasopharynx salivary gland Prior irradiation 4575 Gy majority ( 75 % great ) tumor volume Entire tumor volume must include treatment field limit total spinal cord dose ( prior anticipate ) 50 Gy Prior radiotherapy record , include simulation portal film , available order assure cord tolerance exceed Measurable disease Ineligible complete surgical resection No distant metastases PATIENT CHARACTERISTICS : Age : 18 Performance status : Zubrod 0 1 Life expectancy : No concurrent illness would limit survival Hematopoietic : Granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 mg/dL Serum glutamate oxaloacetate transaminase ( SGOT ) serum glutamate pyruvate transaminase ( SGPT ) great 2 time normal* Alkaline phosphatase great 2 time normal* * Greater 2 time normal allowed metastasis liver ultrasound CT scan Renal : Creatinine great 1.5 mg/dL Other : No invasive malignancy within past 2 year except situ malignancy ( e.g. , carcinoma situ cervix , carcinoma situ breast , nonmelanoma skin cancer ) No concurrent illness would impair tolerance therapy No grade 2 bad preexist peripheral sensory neuropathy No hypersensitivity E. coli derive product Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Prior chemotherapy allow component primary treatment No prior chemotherapy recurrent disease At least 6 month since prior chemotherapy Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics At least 6 month since prior radiotherapy Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>recurrent metastatic squamous neck cancer occult primary</keyword>
	<keyword>metastatic squamous neck cancer occult primary squamous cell carcinoma</keyword>
	<keyword>stage I squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage II squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage III squamous cell carcinoma lip oral cavity</keyword>
	<keyword>recurrent squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage I squamous cell carcinoma oropharynx</keyword>
	<keyword>stage II squamous cell carcinoma oropharynx</keyword>
	<keyword>stage III squamous cell carcinoma oropharynx</keyword>
	<keyword>recurrent squamous cell carcinoma oropharynx</keyword>
	<keyword>stage I squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage II squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage III squamous cell carcinoma hypopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage I squamous cell carcinoma larynx</keyword>
	<keyword>stage II squamous cell carcinoma larynx</keyword>
	<keyword>stage III squamous cell carcinoma larynx</keyword>
	<keyword>recurrent squamous cell carcinoma larynx</keyword>
	<keyword>stage I squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>stage II squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>stage III squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent squamous cell carcinoma paranasal sinus nasal cavity</keyword>
</DOC>